Please login to the form below

Not currently logged in
Email:
Password:

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

Lilly’s Olumiant combined with Gilead’s remdesivir hits the mark in COVID-19

A study of Eli Lilly’s JAK inhibitor Olumiant in combination with Gilead’s antiviral med remdesivir met its primary endpoint in patients hospitalised with COVID-19. ... The ACTT-2 trial, which was sponsored by the US National Institute of Allergy and

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Madmicrobe Studios

MadMicrobe is an award-winning team of animators and science experts creating photo real life-science animation content for the healthcare and...

Latest intelligence

talent and leadership
Leadership and talent
Looking at the key objectives of running leadership programmes...
Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....

Infographics